Eris Lifesciences Limited (ERIS.NS) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

+108.8%

₹2,450.28

vs ₹1,173.30 price

Levered DCF

₹815.67

After debt service

Piotroski score

5 / 9

Average

Altman Z-score

3.5

Safe zone

Rating

B+

Overall 3 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2026	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
P/E	28.62×	53.77×	29.5×	20.36×	23.04×	23.13×	17.07×	30.08×
P/B	4.54×	6.64×	4.47×	3.54×	4.9×	5.21×	3.9×	7.61×
P/S	5.67×	6.58×	5.81×	4.68×	7.06×	6.89×	4.78×	9.05×
EV / EBITDA	18.04×	20.47×	20.39×	15.7×	18.38×	18.63×	13.04×	23.68×
Gross margin	47.9%	74.6%	80.5%	78.5%	80.3%	79.7%	113.7%	116.1%
Operating margin	26.9%	24.4%	24.9%	25.4%	32.1%	32.6%	30.6%	32.1%
Net margin	19.8%	12.2%	19.7%	23.0%	30.6%	29.8%	28.0%	30.1%
Current ratio	0.74×	0.89×	0.91×	1.73×	3.14×	2.8×	2.91×	1.9×
Debt / equity	0.6×	0.87×	1.08×	0.4×	0.04×	0×	0.01×	0.15×
Interest coverage	4.36×	3.04×	5.84×	16.13×	100.75×	196.85×	140.83×	13.48×
Dividend yield	0.0%	0.5%	0.0%	1.3%	0.9%	0.9%	0.9%	0.0%
Payout ratio	0.0%	28.4%	0.0%	26.1%	20.1%	21.0%	15.8%	0.0%

Key metrics by fiscal year

Metric	FY2026	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
Return on equity	15.9%	12.3%	15.2%	17.4%	21.3%	22.5%	22.9%	25.3%
Return on invested capital	12.6%	8.5%	6.9%	11.4%	18.8%	21.0%	20.9%	20.0%
Return on assets	8.4%	5.0%	5.6%	10.4%	17.9%	19.4%	19.1%	18.7%
Free cash flow yield	0.3%	4.8%	3.1%	-7.1%	2.7%	4.3%	2.4%	2.1%
Earnings yield	3.5%	1.9%	3.4%	4.9%	4.3%	4.3%	5.9%	3.3%
Enterprise value	₹200.3B	₹212B	₹142.5B	₹86B	₹93.9B	₹81.8B	₹50.1B	₹89.2B
Net debt / EBITDA	2.07×	2.18×	3.85×	1.5×	0.07×	-0.07×	-0.14×	0.45×
Cash conversion cycle (days)	109	59	-58	71	48	33	135	40